Malaria vaccine development paves way for protective therapy

Scientists have made a significant contribution towards the development of a vaccine to prevent malaria.

Researchers have tested a preliminary form of a against the disease, which is spread by the bite of the mosquito and kills more than 600,000 people each year.

Until now, developing malaria vaccines has been challenging. A vaccine must incorporate key proteins from the malaria parasites, which will trigger production of antibodies by the immune system. These proteins have a complex, intricate structure that is hard to reproduce.

Scientists at the University of Edinburgh have now found a novel way to produce proteins that could lead to malaria vaccines being easy and cheap to manufacture. They have grown them inside a tiny single-celled aquatic creature, whose biological make-up is similar to that of the malaria parasite. The organism, and the , can multiply quickly in the lab.

In tests in mice, a vaccine developed using human parasite proteins – known as MSP-1-BBM – enabled the immune system to produce antibodies in the bloodstream. These antibodies were shown to respond to the human , indicating that the vaccine would be likely to trigger an if it were used in people.

Researchers now hope to develop the vaccine for further testing, with the aim of producing a therapy that will be effective in humans. Scientists say there is a pressing need for new treatments, as many forms of the disease are becoming resistant to existing drugs. Children and pregnant women in sub-Saharan Africa are particularly at risk.

The study, carried out in collaboration with the German company Cilia AG and published in the journal PLoS One, was funded by the European Union.

Dr. David Cavanagh, of the University of Edinburgh's School of Biological Sciences, who led the study, said: "There is a desperate need for an effective vaccine, which can be made easily in large quantities, to protect against this devastating disease. Our findings meet this challenge and, with more work, could lead to a vaccine to help those most at risk."

add to favorites email to friend print save as pdf

Related Stories

Australian researchers close in on malaria vaccine

Jul 02, 2013

Australian researchers said Tuesday they were closing in on a potential vaccine against malaria, with a study showing their treatment had protected mice against several strains of the disease.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments